Asked by: Baroness Jones of Moulsecoomb (Green Party - Life peer)
Question to the Department for Science, Innovation & Technology:
To ask His Majesty's Government whether they will publish the letter sent by Lord Vallance of Balham to the Home Secretary following his meeting with the CEO of MBR Acres on 17 September 2025.
Answered by Lord Vallance of Balham - Minister of State (Department for Energy Security and Net Zero)
The Department for Science, Innovation and Technology will not be publishing this letter. Releasing internal correspondence at this stage would prematurely expose discussions that relate to the ongoing development of the government’s position on a sensitive policy area. The issues involve complex regulatory, scientific, and public safety considerations, and ministerial discussions include exploratory thinking, provisional advice, and options that have not yet been finalised.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, if his Department will consider recognising Long Covid as an occupational disease.
Answered by Stephen Timms - Minister of State (Department for Work and Pensions)
The Department is advised by the Industrial Injuries Advisory Council (IIAC), an independent scientific body, on the changes to the list of occupational diseases for which Industrial Injuries Disablement Benefit can be paid.
IIAC has published Command Papers on COVID-19 and its occupational impacts. The Department is considering the recommendations in these documents which can be accessed here: COVID-19 and Occupational Impacts - GOV.UK and Occupational Impact of COVID-19 in the Transport and Education Sectors - GOV.UK
Asked by: Cameron Thomas (Liberal Democrat - Tewkesbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential implications for its policies of the preliminary findings of the ELSA Study that screens children for Type 1 diabetes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is guided by the UK National Screening Committee (UK NSC), an independent scientific advisory committee which makes its recommendations based on internationally recognised criteria and a rigorous evidence review and consultation process. It is only where the committee is confident that screening would provide more good than harm that a screening programme is recommended, as all medical interventions carry an inherent risk.
The UK NSC is aware of the ELSA study and looks forward to receiving the results of this study when the trial is complete.
Asked by: Peter Bedford (Conservative - Mid Leicestershire)
Question to the Home Office:
To ask the Secretary of State for the Home Department, what steps she is taking to ensure that organisations that hold licenses to use animals in science provide those animals with access to food and water; and if she will make an assessment of the potential merits of increasing the sanction given to people who fail to provide access to food and water.
Answered by Dan Jarvis - Minister of State (Cabinet Office)
All licensed establishments must fully uphold the required standards for animal welfare as set out in the Animals (Scientific Procedures) Act 1986 (ASPA) and the Code of Practice for the Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes. This includes clear duties on ensuring animals have access to food and water.
The Animals in Science Regulation Unit (ASRU) audits establishments to assure compliance with these requirements and takes any potential non-compliance very seriously.
Where incidents relating to access to food or water have occurred, ASRU has investigated them in line with its published Compliance Policy Framework, which sets out how potential non-compliance is identified, investigated, and addressed (www.gov.uk/guidance/animal-testing-and-research-compliance-with-aspa).
All cases are thoroughly investigated and ASRU applies the most suitable remedy based on the severity of the incident. A broad range of sanctions are available, and outcomes are published in ASRU’s Annual Report to support learning and ensure transparency. Through consistent delivery of the compliance policy the Regulator aims to drive up standards of welfare.
Asked by: Baroness Penn (Conservative - Life peer)
Question to the Department for Education:
To ask His Majesty's Government what the membership is of the early years screen time advisory group.
Answered by Baroness Smith of Malvern - Minister of State (Department for Work and Pensions)
The early years screen time advisory group is comprised of the following members:
All members of the group attended the first meeting of the early years screen time advisory group on 22 January, alongside officials from the Department for Education, the Department of Health and Social Care and the Office of the Children’s Commissioner for England.
This introductory meeting focused on agreeing ways of working, including delivery timelines and approaches to evidence gathering, and the scope of the early years screen time guidance. The group also discussed the dissemination of the guidance.
Minutes of the meeting will be published in due course.
Asked by: Baroness Penn (Conservative - Life peer)
Question to the Department for Education:
To ask His Majesty's Government who attended the first meeting of the early years screen time advisory group on 22 January; and what was discussed in that meeting.
Answered by Baroness Smith of Malvern - Minister of State (Department for Work and Pensions)
The early years screen time advisory group is comprised of the following members:
All members of the group attended the first meeting of the early years screen time advisory group on 22 January, alongside officials from the Department for Education, the Department of Health and Social Care and the Office of the Children’s Commissioner for England.
This introductory meeting focused on agreeing ways of working, including delivery timelines and approaches to evidence gathering, and the scope of the early years screen time guidance. The group also discussed the dissemination of the guidance.
Minutes of the meeting will be published in due course.
Asked by: Lord Teverson (Liberal Democrat - Life peer)
Question to the Department for Environment, Food and Rural Affairs:
To ask His Majesty's Government whether the steps being taken to reduce the current levels of fipronil and imidacloprid in rivers will result in meeting their mandated obligation to achieve the Water Frameworks Directive’s requirement for good ecological and chemical status by 2027.
Answered by Baroness Hayman of Ullock - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
The Pharmaceuticals in the Environment group, supported by the Veterinary Medicines Directorate, has put in place a roadmap for reducing exposure of these substances to water courses, with workstreams looking at several complementary activities. These include educating vets and the pet-owning public, investing in research to plug scientific evidence gaps, including routes to the environment and pet owner behavioural change, and reviewing the guidance for environmental risk assessments, which will all contribute to the desired aim.
Asked by: Iqbal Mohamed (Independent - Dewsbury and Batley)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, what steps her Department is taking to raise public awareness of the impact of methane-reducing feed additives used in livestock farming.
Answered by Mary Creagh - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
We have a system. Methane-reducing food products, including seaweed, oils and synthetic products such as Bovaer, are a key tool in reducing emissions from agriculture by up to one third. Bovaer is approved for use in 70 countries, including those in the EU, Switzerland, the US, Canada and Australia. We are building the market for safe, effective options and helping farmers to adopt them. Such products are approved by the Food Standards Agency, and that advice has not been changed. Bovaer has been reviewed by 100 peer-reviewed scientific studies.
Asked by: Alex Mayer (Labour - Dunstable and Leighton Buzzard)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, whether Natural England has enacted byelaws under Section 28R of the Wildlife and Countryside Act 1981 for the (a) protection and (b) management of Sites of Special Scientific Interest.
Answered by Mary Creagh - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
Natural England has not enacted any byelaws under section 28R since the provision’s introduction in 2001. A set of Model SSSI Byelaws for this purpose was agreed with Defra in 2020 and was published by Natural England at https://consult.defra.gov.uk/natural-england/byelaws-for-sssis/.
Asked by: Angus MacDonald (Liberal Democrat - Inverness, Skye and West Ross-shire)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, what assessment he has made of the impact of pharmaceutical and medical device R&D site closures on the trends in the levels of UK’s scientific research capacity since 2010.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Government has made no formal assessment of the impact of pharmaceutical and medical device R&D site closures on trends in the UK’s scientific research capacity since 2010.
The Government does monitor the health of the UK life sciences sector, including R&D performed by UK businesses. Office for National Statistics data shows £9.3 billion of pharmaceutical R&D was performed by UK businesses in 2024, accounting for almost 17% of all R&D undertaken by UK businesses.
We are actively working with industry to boost the UK’s competitiveness and significantly grow the volume of private sector R&D and manufacturing in the UK over the next decade. For instance, the up to £520 million Life Sciences Innovative Manufacturing Fund and the pilot £50m Transformational R&D Investment Fund, which are supporting companies like UCB to invest in innovative early manufacturing in the UK.